Pediatrix Medical Group (MD) Stock Analysis & AI Equity Report
Pediatrix Medical Group (MD) overview
Pediatrix Medical Group (MD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,914m and operating profit of USD 209m; the year-end share price was 21.39 USD and market capitalisation was USD 1,775m. Pediatrix Medical Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pediatrix Medical Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Pediatrix Medical Group
Pediatrix Medical Group provides physician services in newborn, maternal-fetal, and other pediatric subspecialty care through affiliated clinicians. Its neonatal teams care for premature or medically complicated babies, primarily in hospital neonatal intensive care units. Maternal-fetal clinicians provide inpatient and office-based care to expectant mothers with complicated pregnancies and their unborn babies. The network also includes pediatric intensivists, hospitalists, and surgeons serving hospital clients and patients.
Generate the Pediatrix Medical Group report
Pediatrix Medical Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pediatrix Medical Group and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Pediatrix Medical Group
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.